Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis

Abstract

Bortezomib, the first potent therapeutic proteasome inhibitor, has been suggested as a standard care in patients with newly diagnosed and relapsed multiple myeloma (MM). However, evidence bearing on the efficacy and safety of subcutaneous (SC) versus intravenous (IV) administration of bortezomib for MM patients is controversial. Randomised controlled trials (RCTs) and observational studies were enrolled in our meta-analysis to investigate the efficacy and safety of bortezomib via SC vs. IV administration on MM patients. Sixteen trials with a total of2575 patients with MM (SC, n=1191; IV, n=1384) were included in our meta-analysis. There were no significant differences between these two arms regarding overall response rate (ORR), complete response (CR), or very good partial response (VGPR). The pooled RRs for rate of adverse events (AEs), such as thrombocytopenia and bortezomib-induced peripheral neuropathy (BIPN), were 0.79 (95% CI: 0.68-0.92) and 0.63 (95% CI: 0.51-0.79), respectively. Moreover, there was much more largely decreased incidence of grade 3 and higher thrombocytopenia and BIPN in bortezomib SC administration than IV route. In general, alternative SC administration should be considered instead of IV administration in use of bortezomib for patients with MM. Key words: bortezomib; multiple myeloma; meta-analysis; subcutaneous administration

Keywords

bortezomib / multiple myeloma / meta-analysis / subcutaneous administration

References

[1] KumarSK, CallanderNS, AlsinaM, et al. . Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cane Netw, 2017, 15(2): 230-269

[2] RomanoA, ChiarenzaA, ConsoliU, et al. . Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. Ann Oncol, 2013, 24(4): 1038-1044 PMID: 23136226

[3] RichardsonPG, BriembergH, JagannathS, et al. . Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol, 2006, 24(19): 3113-3120 PMID: 16754936

[4] RichardsonPG, DelforgeM, BeksacM, et al. . Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 2011, 26(4): 595-608 PMID: 22193964

[5] MateosMV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev, 2010S24-S32

[6] PalumboA, MateosMV, BringhenS, et al. . Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?. Blood Rev, 2011, 25(4): 181-191 PMID: 21497966

[7] MoreauP, CoiteuxV, HulinC, et al. . Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica, 2008, 93(12): 1908-1911 PMID: 18768528

[8] MoreauP, PylypenkoH, GrosickiS, et al. . Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol, 2011, 12(5): 431-440 PMID: 21507715

[9] BMJ, 1994, 309(6964

[10] MargulisAV, PladevallM, Riera-GuardiaN, et al. . Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol, 2014, 6: 359-368 PMID: 25336990 PMCID: 4199858

[11] FernandezLC, KyleRA, DurieBG, et al. . Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia, 2013, 274): 780-791

[12] ReeveBB, McfatrichM, PinheiroLC, et al. . Cognitive Interview-based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Adolescents with Cancer. J Pain Symptom Manage, 2017, 53(4): 759-766 PMID: 28062347 PMCID: 5374011

[13] GaltmanD, FschulzK, MoherD, et al. . The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration. Ann Intern Med, 2017, 134(8): 663-694

[14] HigginsJP, ThompsonSG, DeeksJJ, et al. . Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414): 557-560 PMID: 12958120 PMCID: 192859

[15] StuckAE, RubensteinLZ, WielandD, et al. . Bias in Meta-Analysis Detected by a Simple, Graphical Test. BMJ, 1997, 315(7109): 629-634

[16] LiuH, FuCC, XueSL, et al. . Efficacy and safely study of subcutaneous injection of bortezomib in the treatment of de novo patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi (Chinese), 2013, 34(4): 229-230

[17] WangYS, DingSH, WuF, et al. . Safety and efficacy of subcutaneous administration of bortezomib in the treatment of multiple myeloma. J Sichuan Univ (Med Sei Edition) (Chinese), 2014, 45(3): 529-532

[18] WuS, ZhengC, ChenS, et al. . Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients. Biomed Res Int, 2015, 2015(9): 927 105

[19] XuY, DengS, AnG, et al. . Subcutaneous administration of bortezomib significantly decreased and delayed the development of peripheral neuropathy in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma, 2015, 15: el63-el63

[20] MinarikJ, PavlicekP, PourL, et al. . Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One, 2015, 10(4): e0123 866

[21] MangiacavalliS, CocitoF, FerrettiV, et al. . Subcutaneous versus intravenous bortezomib: a real-life study on multiple myeloma patients. Haematologica, 2015, 100: 519-519

[22] LinY, WangZH, ShangJ, et al. . Clinical comparison of subcutaneous injection and intravenous injection of bortezomib used in BCD treatment program for multiple myeloma. Chin J Clin Rational Drug Use (Chinese), 2016, 9(19): 43-44

[23] YanY, RuanLH, YangHP, et al. . Clinical application of subcutaneous bortezomib administrion for multiple myeloma. Chin J Mod Drug Appl (Chinese), 2014, 8(14): 122-123

[24] ZhangYJ, WuW, GuWY, et al. . Clinical study of subcutaneous bortezomib administration for multiple myeloma. Chin J Mod Drug Appl (Chinese), 2016, 10(6): 155-156

[25] DingYX, GuWY, ZhengZJ, et al. . Observation and nursing care for decreased peripheral neuropathy caused by subcutaneous bortezomib administration for multiple myeloma. J Qiqihar Univ Med (Chinese), 2015, 36(14): 2170-2171

[26] MerzM, SalwenderH, HaenelM, et al. . Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica, 2016, 101(12): e485-e487 PMID: 27540135 PMCID: 5479613

[27] RifkinRM, MaE, HarrellR, et al. . Comparative Effectiveness Research on the Treatment Outcomes of Subcutaneous (SC) and Intravenous (IV) Bortezomib (BTZ) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts). Blood, 2015, 126: 4506

[28] SkvortsovaN, PospelovaT, KovynevI, et al. . Comparative efficacy of subcutaneous and intravenous administration of bortezomib in patinets with newly diagnosed multiple myeloma. Haematologica, 2014, 99: 657-657

[29] LammW, DrachschauerB, EderS, et al. . Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology, 2013, 85(4): 223-227 PMID: 24080991

[30] LiuH, XuR, HuangH. Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma. Exp Ther Med, 2016, 12(5): 3041-3046 PMID: 27882113 PMCID: 5103742

[31] BringhenS, LaroccaA, RossiD, et al. . Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, 116(23): 4745-4753 PMID: 20807892

[32] LassalleA, ThomaréP, FronteauC, et al. . Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared to hospital administration: results of a prospective single-center study. Ann Oncol, 2016, 27(2): 314-318 PMID: 26578729

[33] PetrucciMT, FinsingerP, ChisiniM, et al. . Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits. Patient Prefer Adherence, 2014, 8: 939-946 PMID: 25045252 PMCID: 4094627

[34] WehlerEA, KowalS, HernandezgardunoA, et al. . Estimating the Budget Impact of Switching from Bortezomib Intravenous (Iv) to Bortezomib Subcutaneous (Sq) in the Treatment of Relapsed/Refractory Multiple Myeloma (Mm) in Mexico. Value Health, 2015, 18(7): A818-A818

[35] GozzettiA, CandiV, BrambillaCZ, et al. . Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?. Br J Haematol, 2016, 177(1): 144-147 PMID: 26970245

[36] KurodaJ, MizutaniS, ShimuraY, et al. . Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy. Ann Hematol, 2015, 94(4): 687-689 PMID: 25209844

[37] AtesagagluB, TopcuogluP, MerterM, et al. . Subcutaneous bortezomib is as effective and less neurotoxic than intravenous bortezomib: Ankara University experience. Haematologica, 2015, 100: 740-741

[38] HisamaS, NosakaK, YanoY, et al. . An evaluation of the incidence of adverse events by subcutaneous versus intravenous administration of bortezomib. Meeting of the Japanese-Society-Of-Medical-Oncology, 2014, 43(2): 185-186

[39] RandallKL, BokhariSW, QureshiI. A single centre clinical experience of the efficacy and safety profile of subcutaneous versus intravenous bortezomib. Scientific Meeting of the British-Society-For-Haematology, 201461-61

[40] KohY, LeeSY, KimI, et al. . Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer Chemother Pharmacol, 2014, 74(3): 653-657 PMID: 25096796

[41] LaroccaA, BringhenS, PetrucciMT, et al. . A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. Leukemia, 2016, 30(6): 1320-1326 PMID: 26898189

[42] O'SullivanJM, KumarS, YeomansC, et al. . VMP using weekly and subcutaneous bortezomib is well tolerated and efficacious for newly diagnosed and relapsed myeloma patients. Br J Haematol, 201464-65

[43] SimpsonD, MccullochR L J, et al. . Weekly Subcutaneous Bortezomib Is Well Tolerated and Effective As Initial Therapy Of Symptomatic Myeloma. Blood, 2013, 122: 3229-3229

[44] WangL, WangKF, ChangBY, et al. . Once-weekly Subcutaneous Administration of Bortezomib in Patients with Multiple Myeloma. Asian Pac J Cancer Prev, 2015, 16(5): 2093-2098 PMID: 25773856